Luye Pharma’s Dual TAAR1/5-HT2CR Agonist LY03020 Approved for Clinical Trials in the U.S.
Shanghai, January 14, 2025 – Luye Pharma Group today announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for LY03020, a dual TAAR1/5-HT2CR agonist intended to treat schizophrenia. Developed on the company’s New ...
January 14,2025
Luye Pharma Announces the Approval of Zepzelca® (Lurbinectedin for Injection) by China’s National Medical Products Administration for ...
Shanghai, December 3, 2024 - Luye Pharma Group today announced that the innovative drug Zepzelca® (lurbinectedin for injection) has been approved for marketing by China’s National Medical Products Administration (NMPA) through the priority review program. The drug is indicated ...
December 03,2024
28
2024-11
Luye Pharma’s Ruoxinlin and Other Drugs Included on China’s 2024 National Reimbursement Drug List
11
2024-11
Luye Pharma’s Class 1 Innovative Antidepressant Targeting NET/DAT/GABAAR Approved for Clinical Trials in China
29
2024-08
Luye Pharma Announces 2024 Half Year Results
13
2024-08
Luye Pharma’s mRNA-based Therapeutic HPV Vaccine LY01620 Approved for Clinical Trials in China
05
2024-08
Luye Pharma’s Dual TAAR1/5-HT2CR Agonist LY03020 Approved for Clinical Trials in China
28
2024-07
Luye Pharma Announces U.S. FDA Approval of ERZOFRI® (paliperidone palmitate) Extended-Release Injectable Suspension for Treating Schizophrenia and Schizoaffective Disorder
23
2024-07
Luye Pharma Will Receive RMB 1.6 Billion Strategic Investment for Shenzhen Luye
04
2024-07
Luye Pharma’s Analgesic Drug Mimeixin (Oxycodone Hydrochloride and Naloxone Hydrochloride Sustained-Release Tablets) Approved for Marketing in China
27
2024-06
Luye Pharma’s Manufacturing Facility for Paliperidone Palmitate Extended-release Injectable Suspension (LY03010) Passes FDA’s PAI with No FDA-483 Issued
20
2024-06
Luye Pharma’s Jinyouping (Rotigotine Microspheres for Injection) Approved for Marketing in China
